



25 November 2025

Novartis Pharma AG
Basel, Switzerland
CH-4056

Reference: EudraCT 2019-003489-41 Novartis Protocol ID CADPT03A12101.

A first-in-patient Phase I/II clinical study to investigate the safety and efficacy of genome-edited hematopoietic stem and progenitor cells in subjects with severe complications of sickle cell disease

No patients were enrolled in the EU/EEA for trial CADPT03A12101. The site initially planned in Italy was withdrawn. The study was conducted entirely outside the EU/EEA. No pediatric patients were enrolled, and the trial is not part of a Pediatric Investigation Plan (PIP). Accordingly, no results will be posted on EudraCT.